Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free ALPMY Stock Alerts

Astellas Pharma (ALPMY) Stock Forecast & Price Target

Astellas Pharma logo
$14.67 +0.22 (+1.52%)
As of 05/8/2026 03:55 PM Eastern
Compare

Astellas Pharma - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 5 Analyst Ratings
Sell
0
Hold
3
Buy
2

Based on 5 Wall Street analysts who have issued ratings for Astellas Pharma in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 3 have given a hold rating, and 2 have given a strong buy rating for ALPMY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ALPMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Astellas Pharma and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALPMY Analyst Ratings Over Time

TypeCurrent Forecast
5/9/25 to 5/9/26		1 Month Ago
4/9/25 to 4/9/26		3 Months Ago
2/8/25 to 2/8/26		1 Year Ago
5/9/24 to 5/9/25
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
 N/A
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
 N/A
Hold
3 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingModerate BuyHoldHoldN/A

ALPMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALPMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Astellas Pharma Stock vs. The Competition

TypeAstellas PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted UpsideN/A858.12% Upside15.51% Upside
News Sentiment Rating
Positive News

See Recent ALPMY News
Neutral News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
4/24/2026
Zacks Research logo
Zacks Research
Not Rated
 UpgradeHold ➝ Strong-Buy
3/24/2026
Jefferies Financial Group Inc. logo
Jefferies Financial Group
2 of 5 stars
 UpgradeHold ➝ Strong-Buy
2/16/2026
Smbc Nikko Sec. logo
Smbc Nikko Sec.
Not Rated
 UpgradeHold
1/19/2026
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-Buy ➝ Hold
9/2/2025
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:50 AM ET.


Should I Buy Astellas Pharma Stock? ALPMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, May 5, 2026. Please send any questions or comments about these Astellas Pharma pros and cons to contact@marketbeat.com.

Astellas Pharma
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Astellas Pharma Inc.:

  • The current stock price is around $16.28, which reflects a recent gap down but may present a buying opportunity for investors looking for value.
  • Astellas Pharma Inc. reported strong quarterly earnings, with earnings per share (EPS) of $0.44, significantly exceeding analyst expectations, indicating robust financial health.
  • The company has a solid market capitalization of approximately $29 billion, suggesting stability and the potential for growth in the pharmaceutical sector.
  • Recent upgrades from analysts, including a "strong-buy" rating from Jefferies Financial Group, indicate positive sentiment and confidence in the company's future performance.
  • Astellas Pharma Inc. focuses on key therapeutic areas such as oncology and immunology, which are critical and growing fields in healthcare, potentially leading to innovative product developments.

Astellas Pharma
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Astellas Pharma Inc. for these reasons:

  • The stock has experienced a recent decline, opening lower than its previous close, which may indicate volatility and uncertainty in the market.
  • Analysts have mixed ratings, with several maintaining a "hold" rating, suggesting that there may not be strong upward momentum in the near term.
  • The company's quick ratio is 0.84, which is below 1, indicating potential liquidity concerns that could affect its ability to meet short-term obligations.
  • Despite strong earnings, the overall market sentiment may be cautious due to broader economic factors affecting the pharmaceutical industry.
  • The debt-to-equity ratio of 0.23, while relatively low, still indicates that the company is using some leverage, which could pose risks if market conditions change.

ALPMY Forecast - Frequently Asked Questions

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 3 hold ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALPMY shares.

According to analysts, Astellas Pharma's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Astellas Pharma's stock had 3 upgrades by analysts.

Astellas Pharma has been rated by research analysts at Jefferies Financial Group, Smbc Nikko Sec., and Zacks Research in the past 90 days.

Analysts like Astellas Pharma more than other "medical" companies. The consensus rating for Astellas Pharma is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ALPMY compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Astellas Pharma Recommendations


This page (OTCMKTS:ALPMY) was last updated on 5/9/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel